No results for ‘’
Gland Pharma Ltd
NSE: GLAND BSE: 543245
₹2502.90
(0.56%)
Fri, 07 Aug 2026, 11:23 am
Market Cap (in Cr)41312.5
PE Ratio40.16
Dividend0.72
Health Technology
Pharmaceuticals: Major
24.5KGland Pharma Income Statement
| Particulars | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total revenue | 15.80B | 19.93B | 25.72B | 34.24B | 43.84B | 36.08B | 56.42B | 55.90B |
| Gross profit | 5.33B | 6.72B | 9.17B | 13.19B | 16.03B | 10.98B | 13.77B | 12.58B |
| Operating expenses (excl. COGS) | -1.15B | -980.35M | -1.11B | -1.40B | -2.00B | -2.10B | -3.86B | -3.57B |
| Selling/general/admin expenses, total | -940.31M | -667.65M | -740.09M | -1.03B | -1.42B | -1.40B | -3.25B | -2.85B |
| Research & development | -570.96M | -880.23M | -909.32M | -1.20B | -1.93B | -1.85B | -1.95B | -2.01B |
| Selling/general/admin expenses, other | -369.35M | 212.58M | 169.23M | 166.48M | 511.25M | 443.25M | -1.30B | -839.75M |
| Other operating expenses, total | -211.23M | -312.70M | -371.32M | -370.80M | -578.69M | -699.05M | -613.30M | -729.81M |
| Operating income | 4.18B | 5.73B | 8.06B | 11.79B | 14.03B | 8.88B | 9.91B | 9.01B |
| Non-operating income, total | 837.41M | 1.13B | 1.87B | 1.56B | 2.15B | 1.66B | 1.42B | 1.62B |
| Interest expense, net of interest capitalized | -42.42M | -36.69M | -71.82M | -34.11M | -52.42M | -74.47M | -262.00M | -239.87M |
| Interest capitalized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-operating income, excl. interest expenses | 879.82M | 1.36B | 1.94B | 1.60B | 2.19B | 2.30B | 1.65B | 1.86B |
| Non-operating interest income | 271.68M | 433.13M | 514.86M | 859.49M | 1.39B | 1.79B | 1.51B | 2.04B |
| Miscellaneous non-operating expense | 608.14M | 931.50M | 1.43B | 736.43M | 801.40M | 509.90M | 142.95M | -184.91M |
| Unusual income/expense | 10.00K | -200.00M | 1.07M | 0 | 15.70M | -564.61M | 31.08M | 0 |
| Pretax income | 5.01B | 6.86B | 9.93B | 13.35B | 16.19B | 10.55B | 11.33B | 10.63B |
| Taxes | -1.80B | -2.34B | -2.20B | -3.38B | -4.07B | -2.74B | -3.60B | -3.64B |
| Non-controlling/minority interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| After tax other income/expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income before discontinued operations | 3.21B | 4.52B | 7.73B | 9.97B | 12.12B | 7.81B | 7.72B | 6.99B |
| Net income | 3.21B | 4.52B | 7.73B | 9.97B | 12.12B | 7.81B | 7.72B | 6.99B |
| Dilution adjustment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Preferred dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted net income available to common stockholders | 3.21B | 4.52B | 7.73B | 9.97B | 12.12B | 7.81B | 7.72B | 6.99B |
| Basic earnings per share (Basic EPS) | - | - | - | - | - | - | - | - |
| Diluted earnings per share (Diluted EPS) | - | - | - | - | - | - | - | - |
| EBITDA | 4.96B | 6.56B | 9.00B | 12.77B | 15.14B | 10.35B | 13.35B | 12.79B |
| EBIT | 4.18B | 5.73B | 8.06B | 11.79B | 14.03B | 8.88B | 9.91B | 9.01B |
| Total operating expenses | -11.62B | -14.20B | -17.66B | -22.45B | -29.81B | -27.20B | -46.51B | -46.90B |
| Prepaid expenses | 103.75M | 85.17M | 91.22M | 109.11M | 141.61M | 138.22M | 384.65M | 392.40M |
| Deferred income, current | 535.83M | 389.17M | 342.31M | 342.47M | 339.16M | 760.42M | 853.75M | 1.92B |
| Capital and operating lease obligations | 11.41M | 10.51M | 9.25M | 7.64M | 6.61M | 4.83M | 346.79M | 294.87M |
| Operating lease liabilities | — | — | — | — | — | — | — | — |
| Deferred tax liabilities | 957.14M | 1.08B | 740.54M | 738.81M | 954.14M | 1.07B | 2.20B | 2.15B |
| Deferred income, non-current | — | — | — | — | — | — | 404.86M | 413.85M |
| Minority interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in accrued expenses | — | — | — | — | — | — | — | — |
| Common dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.29B |
| Preferred dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |